Get the Stockscreener App
51.28
0.19%
-0.10
Pre-market:
50.80
-0.48
-0.94%
Moderna Inc stock is traded at $51.28, with a volume of 5.97M.
It is down -0.19% in the last 24 hours and up +1.97% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$51.38
Open:
$51.2335
24h Volume:
5.97M
Relative Volume:
0.52
Market Cap:
$20.34B
Revenue:
$1.94B
Net Income/Loss:
$-2.82B
P/E Ratio:
-7.0617
EPS:
-7.2617
Net Cash Flow:
$-2.08B
1W Performance:
-3.81%
1M Performance:
+1.97%
6M Performance:
+98.84%
1Y Performance:
+57.01%
1-Day Range:
$50.19
$52.55
1-Week Range:
$50.19
$56.51
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
51.28 | 20.34B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 31.04B | 606.42M | -1.28B | -997.58M | -6.403 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Inc. stock faces analyst pressure amid patent settlement with Arbutus Biopharma - AD HOC NEWS
Moderna's Spikevax Vaccine: Current Status and Future Prospects in mRNA Technology Evolution - AD HOC NEWS
Lobbying Update: $100,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Moderna's Spikevax Vaccine: Latest Developments and Future Prospects as of March 2026 - AD HOC NEWS
ABUS: $2.25B Moderna settlement and improved net loss highlight strong 2025 performance - TradingView
ABUS: Secured $950M settlement with Moderna, reduced net loss, and streamlined operations in 2025 - TradingView
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA - MarketBeat
VIX Spike: Is Moderna Inc a momentum stock2026 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Rate Hike: Should you avoid Moderna Inc stock right nowAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Trade Recap: Is now the right time to enter Moderna Inc2026 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
Moderna Inc. stock faces headwinds amid pipeline delays and FDA vaccine policy shifts - AD HOC NEWS
Aug Macro: Can Moderna Inc continue delivering strong returnsWeekly Stock Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
Moderna's Spikevax Vaccine Faces Renewed Scrutiny Amid Biotech Sector Momentum and Safety Data Revel - AD HOC NEWS
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
COMMENTARY: An erratic FDA is a threat to innovation - Jefferson City News Tribune
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest - Yahoo Finance UK
What triggered Moderna shares' latest price pullback - Traders Union
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review - Yahoo Finance UK
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
MODERNA, INC. (MRNA) - MSN
Moderna shares see a dip: what is pressuring the stock - Traders Union
Moderna shares see a jump — What is fueling the stock rise - Traders Union
Federal Judge Blocks RFK Jr. Vaccine Policy Shift: Spikevax's Path Forward Stabilized - AD HOC NEWS
Militia Capital Partners LP Sells 49,000 Shares of Moderna, Inc. $MRNA - MarketBeat
Times Opinion: An erratic FDA is a threat to innovation - Chattanooga Times Free Press
Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 millionSEC filing - marketscreener.com
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery - FinancialContent
Form DEFA14A Moderna, Inc. - StreetInsider
US Health Secretary Kennedy's vaccine actions and policy positions - marketscreener.com
Moderna, Inc. Trade Ideas — LS:A2N9D9 - TradingView
Moderna Clears Legal Hurdle and Advances Vaccine Pipeline - AD HOC NEWS
Moderna (MRNA) Is Down 5.7% After Costly LNP Settlement And Multi-Pathogen Trial UpdateHas The Bull Case Changed? - simplywall.st
An erratic FDA is a threat to innovation - The Korea Times
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh Focus - Yahoo Finance
Moderna Impfstoff Spikevax 2025-2026: What Changed This Year - AD HOC NEWS
Moderna Impfstoff (Spikevax) in 2026: Key Updates - AD HOC NEWS
Moderna (MRNA) Valuation Check After Sharp Multi‑Month Share Price Rebound - simplywall.st
Moderna Impfstoff (Spikevax): What Changed in 2026 - AD HOC NEWS
Moderna (MRNA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits - JD Supra
Why is Moderna stock down today? - Traders Union
3 Healthcare Stocks to Avoid in 2026: Analysis of UnderperformersNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):